Description CJC-1295 NO DAC + Ipamorelin GHRH Analog & GHRP Research Blend Research Overview This is a research blend combining two distinct peptides that engage the growth hormone (GH) axis through complementary mechanisms: CJC-1295 (no DAC), a modified GHRH (growth hormone-releasing hormone) analog, and Ipamorelin, a selective ghrelin receptor (GHSR-1a) agonist functioning as a growth hormone-releasing peptide (GHRP)
W.et al (2018a)
If you are considering compounded semaglutide or tirzepatide and have concerns about sleep disruption, discussing your genetic predispositions with your provider before starting can shape dosing strategies, timing, and adjunctive support decisions
A total of 17,609 participants were enrolled by the investigators
Elaine Phuah, DO, MBA, FACOI, and our team specialize in medical weight loss
Regular use promotes a radiant, even-toned complexion